2017 American Transplant Congress
Impact of Donor Genotype on Recipient Tacrolimus Pharmacokinetics: The Liver Matters.
1U of Cinicnnati, Cincinnati; 2Cincinnati Children's, Cincinnati; 3iC42 Clinical Research, Colorado
Tacrolimus (Tac) is a cornerstone immunosuppressant metabolized in the gut and liver, resulting in high intra/inter patient pharmacokinetic (PK) variability. Recipient genotype (RG) impacts tac…2017 American Transplant Congress
Reduced Conversion from IgM Anti-HLA-DSA to IgG Anti-HLA-DSA in Belatacept-Treated vs. Cyclosporine-Treated Patients in BENEFIT and BENEFIT-EXT Trials.
Post-transplant, up to 50% of recipients develop IgM DSA. Half of these patients go on to develop IgG DSA. Importantly, patients that progress to IgG…2017 American Transplant Congress
Mesenchymal Stem Cells Suppress T Cell Proliferation and Improve Allograft Survival in a Nonhuman Primate Transplant Model.
Emory Transplant Center, Emory University, Atlanta, GA
Background: The clinical implementation of costimulation blockade (CoB) provides long-term benefit to transplant recipients, with the short-term drawback of increased acute rejection. Cellular therapies are…2017 American Transplant Congress
Emerging Safety and Tolerability of Obinutuzumab, a Type 2 Anti-CD20 Monoclonal Antibody for the Desensitization of Renal Transplant Candidates.
Background: Rituximab has limited efficacy for desensitizing allosensitized patients (pts) with end-stage renal disease (ESRD) and enabling kidney transplantation (KTx), however, tissue B-cell depletion is…2017 American Transplant Congress
Down but Not Out: Leucopenia Can Be Safely Treated with Reduction in Immunosuppression without Increasing Risk to the Kidney Allograft.
IntroductionLeucopenia is a growing problem with increasing immunosuppression (IS) in kidney transplantation. Reducing IS in the face of leucopenia is a concern due to the…2017 American Transplant Congress
Incidence of Donor-Specific Anti-HLA Antibodies in Non-HLA Sensitized Patients Given Tacrolimus Once or Twice Daily During the First Two Years Post-Transplantation.
Department of Nephrology and Organ Transplantation, Toulouse University Hospital, Toulouse, France
Donor-specific anti-HLA antibody (DSA)-mediated rejection (AMR) is a main cause of graft loss after kidney transplantation. Non-adherence is a risk factor for AMR and graft…2017 American Transplant Congress
Conservative Management of Pneumatosis Intestinalis After Pediatric Liver Transplantation.
BACKGROUND: Pnuematosis intestinalis (PI), characterized by gas in the bowel wall, is a rare pathologic finding in pediatric liver transplantation (PLT) recipients. PI has been…2017 American Transplant Congress
A Novel MyD88 Inhibitor Attenuates Allograft Rejection in Heterotopic Tracheal Transplantation in Mice.
Background: Obstructive bronchiolitis (OB) characterized by chronic rejection, is the main complication after lung transplantation which limits the long-term survival of the recipients. Innate immune…2017 American Transplant Congress
Tacrolimus Dose Variability, CYP3A5 Genotype, and Acute Rejection in African American and European American Kidney Transplant Recipients.
Background: Poor immunosuppression with tacrolimus (TAC) after kidney transplantation contributes to the development of toxicity and loss of efficacy. We aimed to associate intra-patient TAC…2017 American Transplant Congress
Determinants of Successful Use of Sirolimus in Renal Transplantation.
Sirolimus (SLR) is an established component in the immunosuppressive treatment after renal transplantation.The side effects of SLR differ from other immunosuppressants and may limit its…
- « Previous Page
- 1
- …
- 84
- 85
- 86
- 87
- 88
- …
- 138
- Next Page »